SGLT2 inhibitors have been shown in multiple randomized trials to reduce the risk of major adverse cardiovascular events (MACE) (death, myocardial infarction and stroke) and major adverse kidney events (MAKE) (death, eGFR decline > 50% and end-stage kidney disease (ESKD))6–9. The gene discussed is SLC5A2; the disease is myocardial infarction.